Resalis Therapeutics S.r.l.

https://www.resalistherapeutics.com

LinkedIn: https://www.linkedin.com/company/resalistherapeutics

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders. *

	Start	2021-01-01 established
	Industry	RES-010 (Resalis Therapeutics, antisense oligonucleotide targeting miR-22)
	Industry 2	non-coding RNA
	Person	Toniolo, Alessandro (Resalis Therapeutics 202302 CEO before Pfizer + Novartis)
	Person 2	Puglisi, Pietro (Claris Ventures 201907 Managing Partner + Co-Founder)

	Region	Torino (Turin) (TO)
	Country	Italy
	Street	52 Via Nizza
	City	10126 Torino (TO)
		Address record changed: 2023-03-05

Basic data	Employees	n. a.

		* Document for »About Section«: Resalis Therapeutics S.r.l.. (2/22/23). "Press Release: Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases". Torino.

		Record changed: 2023-07-10

Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x200px

More documents for Resalis Therapeutics S.r.l.

[1] Resalis Therapeutics S.r.l.. (2/22/23). "Press Release: Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases". Torino....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]